Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia

Magister Public Health - MPH === Antiretroviral regimens have side effects that can threaten adherence by patients resulting in evolution of viral resistance due to suboptimal drug levels. Studies have shown that drug adherence of at least 80% can result in viral load suppression. There is no litera...

Full description

Bibliographic Details
Main Author: Gorova, Vivianne Inganai
Other Authors: Igumbor, Ehimario
Language:en
Published: University of the Western Cape 2013
Subjects:
Online Access:http://hdl.handle.net/11394/2382
id ndltd-netd.ac.za-oai-union.ndltd.org-uwc-oai-etd.uwc.ac.za-11394-2382
record_format oai_dc
spelling ndltd-netd.ac.za-oai-union.ndltd.org-uwc-oai-etd.uwc.ac.za-11394-23822017-08-02T04:00:14Z Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia Gorova, Vivianne Inganai Igumbor, Ehimario Kasvosve, Ishmael School of Public Health Faculty of Community and Health Sciences Human Immunodeficiency Virus (HIV) Viral load Self- reported Adherence Initiation of therapy First-line therapy Antiretroviral (ARV) therapy Patients Highly Active Antiretroviral Therapy (HAART) Adult Namibia Magister Public Health - MPH Antiretroviral regimens have side effects that can threaten adherence by patients resulting in evolution of viral resistance due to suboptimal drug levels. Studies have shown that drug adherence of at least 80% can result in viral load suppression. There is no literature on the association between the level of adherence to antiretroviral therapy and the degree of virological suppression in Namibia. The aim of the present study was to determine the therapeutic and virological outcomes in HIV/AIDS patients at 6 and 12 months after initiation of highly-active antiretroviral therapy (HAART) in an urban population in Namibia. The distribution of viral load results showed a low uptake (35%) of virological monitoring at 6 month time point and even lower (12%) at 12 months. A conservative viral load threshold for virological response is required in the Namibian setting. The current adherence level of >80% encourage increased ARV therapy rollout. Poor virological outcome was associated with self-reported adherence. South Africa 2013-10-28T07:29:00Z 2011/03/03 10:35 2011/03/03 2013-10-28T07:29:00Z 2010 Thesis http://hdl.handle.net/11394/2382 en University of the Western Cape University of the Western Cape
collection NDLTD
language en
sources NDLTD
topic Human Immunodeficiency Virus (HIV)
Viral load
Self- reported Adherence
Initiation of therapy
First-line therapy
Antiretroviral (ARV) therapy
Patients
Highly Active Antiretroviral Therapy (HAART)
Adult
Namibia
spellingShingle Human Immunodeficiency Virus (HIV)
Viral load
Self- reported Adherence
Initiation of therapy
First-line therapy
Antiretroviral (ARV) therapy
Patients
Highly Active Antiretroviral Therapy (HAART)
Adult
Namibia
Gorova, Vivianne Inganai
Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
description Magister Public Health - MPH === Antiretroviral regimens have side effects that can threaten adherence by patients resulting in evolution of viral resistance due to suboptimal drug levels. Studies have shown that drug adherence of at least 80% can result in viral load suppression. There is no literature on the association between the level of adherence to antiretroviral therapy and the degree of virological suppression in Namibia. The aim of the present study was to determine the therapeutic and virological outcomes in HIV/AIDS patients at 6 and 12 months after initiation of highly-active antiretroviral therapy (HAART) in an urban population in Namibia. The distribution of viral load results showed a low uptake (35%) of virological monitoring at 6 month time point and even lower (12%) at 12 months. A conservative viral load threshold for virological response is required in the Namibian setting. The current adherence level of >80% encourage increased ARV therapy rollout. Poor virological outcome was associated with self-reported adherence. === South Africa
author2 Igumbor, Ehimario
author_facet Igumbor, Ehimario
Gorova, Vivianne Inganai
author Gorova, Vivianne Inganai
author_sort Gorova, Vivianne Inganai
title Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
title_short Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
title_full Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
title_fullStr Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
title_full_unstemmed Therapeutic and virological outcomes in adults living with HIV / AID at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in Namibia
title_sort therapeutic and virological outcomes in adults living with hiv / aid at 6 and 12 months after initiation of first-line highly active antiretroviral therapy in an urban population in namibia
publisher University of the Western Cape
publishDate 2013
url http://hdl.handle.net/11394/2382
work_keys_str_mv AT gorovavivianneinganai therapeuticandvirologicaloutcomesinadultslivingwithhivaidat6and12monthsafterinitiationoffirstlinehighlyactiveantiretroviraltherapyinanurbanpopulationinnamibia
_version_ 1718510329124618240